^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ADAM17 overexpression

i
Other names: ADAM17, ADAM Metallopeptidase Domain 17, CSVP, Disintegrin And Metalloproteinase Domain-Containing Protein 17, Tumor Necrosis Factor, Alpha, Converting Enzyme, Snake Venom-Like Protease, TNF-Alpha Convertase, CD156B, TACE, ADAM Metallopeptidase Domain 18, TNF-Alpha Converting Enzyme, TNF-Alpha-Converting Enzyme, CD156b Antigen, ADAM 17, ADAM18, NISBD1, ADAM17, NISBD
Entrez ID:
Twitter
Trials
1m
miR-4299 inhibits tumor progression in pancreatic cancer through targeting ADAM17. (PubMed, Mol Cell Biochem)
miR-4299 exerted suppressive effects on PC cell proliferation, invasion, and immune escape via targeting ADAM17 expression. This study revealed a novel miR-4299/ADAM17 axis-modulating PC progression and proposed to concern the immune regulatory mechanism of miRNAs in PC development.
Journal
|
ADAM17 (ADAM Metallopeptidase Domain 17) • MIR4299 (MicroRNA 4299) • NKG2D (killer cell lectin like receptor K1)
|
ADAM17 overexpression • miR-429 expression
4ms
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab. (PubMed, Diagnostics (Basel))
To find prognostic factors for advanced ovarian cancer patients undergoing first-line therapy with carboplatin, paclitaxel and bevacizumab, we investigated the expression of a disintegrin and metalloprotease 17 (ADAM17) in cancer tissues. ADAM17 has been involved in ovarian cancer development, progression and cell resistance to cisplatin...However, after the application of a shrinkage procedure to adjust for overfitting hazard ratio estimates, the ADAM17 value as prognostic factor was lost. As subgroup analysis suggested that ADAM17 expression could be prognostically relevant in cases with no residual disease at baseline, further studies in this patient category may be worth planning.
Journal
|
ADAM17 (ADAM Metallopeptidase Domain 17)
|
ADAM17 overexpression
|
Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel
over1year
Exosome-Derived ADAM17 Promotes Liver Metastasis in Colorectal Cancer. (PubMed, Front Pharmacol)
Moreover, exosomal ADAM17 overexpression as well as RNA interference results highlighted its function as a tumor metastasis-promoting factor in colorectal cancer in vitro and in vivo. Taken together, our current work suggests that exosomal ADAM17 is involved in pre-metastatic niche formation and may be utilized as a blood-based biomarker of colorectal cancer metastasis.
Journal
|
CDH1 (Cadherin 1) • ADAM17 (ADAM Metallopeptidase Domain 17)
|
ADAM17 overexpression
over1year
ADAM17 and NF-κB p65 form a positive feedback loop that facilitates human esophageal squamous cell carcinoma cell viability. (PubMed, Int J Clin Exp Pathol)
In addition, western blot analyses and ChIP-qPCR indicated that ADAM17 was responsible for the persistent activation of NF-κB p65 and contributed to ADAM17 expression in ESCC cells. In conclusion, we propose that ADAM17-activated NF-κB p65 signaling positively regulates ADAM17 expression, and facilitates ESCC cell viability.
Journal
|
ADAM17 (ADAM Metallopeptidase Domain 17) • RELA (RELA Proto-Oncogene)
|
ADAM17 overexpression
over1year
Rosmarinic acid inhibits proliferation and migration, promotes apoptosis and enhances cisplatin sensitivity of melanoma cells through inhibiting ADAM17/EGFR/AKT/GSK3β axis. (PubMed, Bioengineered)
In conclusion, RA exerted obvious inhibitory effect on melanoma cell proliferation, migration and invasion, but promotive effect on cells apoptosis. Addition, the showing of this characteristic of RA may rely on inhibiting the expression of ADAM17/EGFR/AKT/GSK3β axis.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • MMP2 (Matrix metallopeptidase 2) • ADAM17 (ADAM Metallopeptidase Domain 17) • MMP9 (Matrix metallopeptidase 9) • GSK3B (Glycogen Synthase Kinase 3 Beta)
|
EGFR expression • BCL2 expression • ADAM17 overexpression
|
cisplatin